ºê·£µå Á¦³×¸¯ ½ÃÀå, Á¡À¯À², ±Ô¸ð, µ¿Çâ, »ê¾÷ ºÐ¼® º¸°í¼­ : ÀǾàǰ À¯Çüº°, ¿ëµµº°, Åõ¿© °æ·Îº°, À¯Åë ä³Îº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2023-2032³â)
Branded Generics Market Share, Size, Trends, Industry Analysis Report, By Drug Class ; By Application; By Route of Administration; By Distribution Channel; By Region, And Segment Forecasts, 2023 - 2032
»óǰÄÚµå : 1339165
¸®¼­Ä¡»ç : Polaris Market Research
¹ßÇàÀÏ : 2023³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 117 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,250 £Ü 6,003,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,250 £Ü 7,415,000
PDF (Multi User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ 20¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,250 £Ü 8,828,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

Polaris Market ResearchÀÇ ÃֽŠÁ¶»ç¿¡ µû¸£¸é, ºê·£µå Á¦³×¸¯ ¼¼°è ½ÃÀå ±Ô¸ð´Â 2032³â±îÁö 4,108¾ï 6,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ º¸°í¼­´Â ÇöÀç ½ÃÀå ¿ªÇп¡ ´ëÇÑ ÀÚ¼¼ÇÑ ÅëÂû·Â°ú ÇâÈÄ ½ÃÀå ¼ºÀå¿¡ ´ëÇÑ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

´ç´¢º´, °íÇ÷¾Ð, ¾Ï°ú °°Àº ¸¸¼ºÁúȯ Áõ°¡À²ÀÌ ÀǾàǰ ¼ö¿ä¸¦ ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ºê·£µå Á¦³×¸¯ ÀǾàǰÀº °í°¡ÀÇ ºê·£µå ÀǾàǰÀ» ´ëüÇÒ ¼ö ÀÖ´Â º¸´Ù Àú·ÅÇÑ ´ë¾ÈÀ» Á¦°øÇϱ⠶§¹®¿¡ ¸¸¼º ÁúȯÀ» ¾Î°í Àִ ȯÀڵ鿡°Ô º¸ÆíÀûÀÎ ¼±ÅÃÀÌ µÇ°í ÀÖ½À´Ï´Ù. Á¦³×¸¯ ÀǾàǰÀÇ º¸±Þµµ ºê·£µå Á¦³×¸¯ ½ÃÀåÀ» °ßÀÎÇÏ´Â ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù.

Á¦³×¸¯ ÀǾàǰÀº ǰÁú, ¾ÈÀü¼º, È¿´ÉÀÌ ¿À¸®Áö³Î ÀǾàǰ°ú µ¿µîÇϱ⠶§¹®¿¡ ÀÇ»ç¿Í ȯÀÚ ¸ðµÎ¿¡°Ô ´õ ³Î¸® ¹Þ¾Æµé¿©Áö°í ÀÖ½À´Ï´Ù. Àüü ÀÇ·áºñ Àý°¨À» À§ÇØ Á¦³×¸¯ ÀǾàǰ »ç¿ëÀ» Àå·ÁÇÏ´Â Á¤ºÎÀÇ ÀÌ´Ï¼ÅÆ¼ºêµµ ºê·£µå Á¦³×¸¯ ÀǾàǰ ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù. ¼¼°è °¢±¹ Á¤ºÎ´Â ÀÇ·áºñ¸¦ Àý°¨Çϰí ȯÀÚµéÀÌ Àú·ÅÇÑ °¡°ÝÀ¸·Î ÀǾàǰÀ» ÀÌ¿ëÇÒ ¼ö ÀÖµµ·Ï Çϱâ À§ÇØ Á¦³×¸¯ ÀǾàǰ »ç¿ëÀ» Àå·ÁÇϰí ÀÖ½À´Ï´Ù.

°¨¿°¼º ¹× ºñ°¨¿°¼º Áúȯ Áõ°¡´Â ³ëÀÎ Àα¸ Áõ°¡¿Í ÇÔ²² ÇコÄÉ¾î »ê¾÷ÀÇ ¼ºÀå¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ´ç´¢º´, °íÇ÷¾Ð, ºñ¸¸°ú °°Àº ¸¸¼ºÁúȯÀº ¼¼°èÀûÀ¸·Î È®»êµÇ°í ÀÖÀ¸¸ç, ³ë³âÃþÀº ÀÌ·¯ÇÑ Áúº´¿¡ ´õ Ãë¾àÇÕ´Ï´Ù.

±× °á°ú, ºê·£µå Á¦³×¸¯À» Æ÷ÇÔÇÑ ÇコÄÉ¾î ¼­ºñ½º ¹× Á¦Ç°¿¡ ´ëÇÑ ¼ö¿ä°¡ Å©°Ô Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, NCBIÀÇ ³í¹®¿¡ µû¸£¸é 2021³â¿¡´Â ¼¼°èÀûÀ¸·Î 5¾ï 3,700¸¸ ¸íÀÇ ´ç´¢º´ ȯÀÚ°¡ ÀÖÀ» °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ´ç´¢º´Àº ¸¸¼º ÁúȯÀ¸·Î Áö¼ÓÀûÀÎ Ä¡·á¿Í °ü¸®°¡ ÇÊ¿äÇÕ´Ï´Ù. ºê·£µå Á¦³×¸¯Àº °í°¡ÀÇ ¿À¸®Áö³Î ÀǾàǰÀ» ´ëüÇÒ ¼ö ÀÖ´Â º¸´Ù Àú·ÅÇÑ ´ë¾ÈÀ» Á¦°øÇϱ⠶§¹®¿¡ ´ç´¢º´ ȯÀڵ鿡°Ô Àαâ ÀÖ´Â ¼±ÅÃÀÌ µÇ°í ÀÖ½À´Ï´Ù.

°íÇ÷¾Ð ¿ª½Ã ³ëÀÎµé »çÀÌ¿¡¼­ ¸¸¿¬ÇÑ ¸¸¼º ÁúȯÀÔ´Ï´Ù. ¼¼°èº¸°Ç±â±¸(WHO)¿¡ µû¸£¸é °íÇ÷¾ÐÀº ¼¼°è 10¾ï ¸í¿¡°Ô ¿µÇâÀ» ¹ÌÄ¡°í ÀÖÀ¸¸ç, 2025³â¿¡´Â 15¾ï ¸íÀ¸·Î ´Ã¾î³¯ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ºê·£µå Á¦³×¸¯Àº °íÇ÷¾Ð¿¡ ´ëÇÑ ÇÕ¸®ÀûÀÎ °¡°ÝÀÇ Ä¡·á ¿É¼ÇÀ» Á¦°øÇÔÀ¸·Î½á ½ÃÀå ¼ö¿ä¸¦ ÁÖµµÇϰí ÀÖ½À´Ï´Ù.

ºê·£µå Á¦³×¸¯ ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

°í·ÉÃþÀÇ ½ÉÀå Áúȯ Áõ°¡¿Í Àú·ÅÇÑ ´ëüǰÀÇ °¡¿ë¼ºÀ¸·Î ÀÎÇØ Ç×°íÇ÷¾ÐÁ¦ ºÎ¹®ÀÌ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

°æ±¸¾à ºÎ¹®Àº ÃÖ¼ÒÇÑÀÇ °£È£ °æÇèÀ¸·Î °æ±¸¿ë ¾à¹°À» Åõ¿©ÇÒ ¼ö ÀÖ°í, ȯÀÚÀÇ ¼ö¿ë¼ºÀÌ ³ô´Ù´Â ÀåÁ¡À¸·Î ÀÎÇØ ½ÃÀå Á¡À¯À²ÀÌ ³ô½À´Ï´Ù.

ÁÖ·Î ½ÅÈï±¹ ½ÃÀå¿¡¼­ ¼Ò¸Å ¾à±¹ ¼ö°¡ Áõ°¡ÇÔ¿¡ µû¶ó ¼Ò¸Å ¾à±¹ÀÇ ¸ÅÃâ Á¡À¯À²ÀÌ È®´ëµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

APACÀº Àú°¡ ÀǾàǰ¿¡ ´ëÇÑ ¼±È£µµ°¡ ³ô¾ÆÁü¿¡ µû¶ó Á¶»ç ±â°£ µ¿¾È ³ôÀº ¼ºÀå·üÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­·Ð

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå Á¶»ç ¹æ¹ý

Á¦4Àå ¼¼°èÀÇ ºê·£µå Á¦³×¸¯ ½ÃÀå¿¡ °üÇÑ ÀλçÀÌÆ®

Á¦5Àå ¼¼°èÀÇ ºê·£µå Á¦³×¸¯ ½ÃÀå, ¾àÁ¦ Ŭ·¡½ºº°

Á¦6Àå ¼¼°èÀÇ ºê·£µå Á¦³×¸¯ ½ÃÀå, ¿ëµµº°

Á¦7Àå ¼¼°èÀÇ ºê·£µå Á¦³×¸¯ ½ÃÀå, À¯Åë ä³Îº°

Á¦8Àå ¼¼°èÀÇ ºê·£µå Á¦³×¸¯ ½ÃÀå, Áö¿ªº°

Á¦9Àå °æÀï ±¸µµ

Á¦10Àå ±â¾÷ °³¿ä

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The global branded generics market size is expected to reach USD 410.86 billion by 2032, according to a new study by Polaris Market Research. The report "Branded Generics Market Share, Size, Trends, Industry Analysis Report, By Drug Class (Alkylating Agents, Antimetabolites, Anti-Hypertensive); By Application; By Route of Administration; By Distribution Channel; By Region, And Segment Forecasts, 2023 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Increasing rates of chronic diseases such as diabetes, hypertension, and cancer are driving the demand for drugs. Branded generics are becoming a popular choice for patients suffering from chronic illnesses as they offer a more affordable alternative to expensive brand-name drugs. The widespread use of generic drugs is another factor driving the branded generics market.

Generic drugs have become more widely accepted by both physicians and patients as they are equivalent in quality, safety, and efficacy to their brand-name counterparts. Government initiatives promoting the use of generic drugs to reduce overall healthcare costs are also driving the growth of the branded generics market. Governments worldwide are promoting the use of generic drugs to lower healthcare costs and increase access to affordable medicines for patients.

Growing burden of infectious and non-infectious diseases, along with the rising geriatric population, is expected to have a positive impact on the healthcare industry's growth. Chronic diseases such as diabetes, hypertension, and obesity are becoming more prevalent worldwide, and the geriatric population is more susceptible to these diseases.

As a result, the demand for healthcare services and products, including branded generics, is expected to increase significantly. According to an NCBI article, there were 537 million patients suffering from diabetes globally in 2021. Diabetes is a chronic disease that requires ongoing medical care and management. Branded generics are becoming a popular choice for diabetic patients as they offer a more affordable alternative to expensive brand-name drugs.

Hypertension is another chronic disease that is prevalent among the geriatric population. According to the World Health Organization (WHO), hypertension impacts 1 Bn people globally, and this is expected to rise to 1.5 Bn, by 2025. Branded generics offer an affordable treatment option for hypertension, which is driving their demand in the market.

Branded Generics Market Report Highlights

Anti-hypersensitive segment accounted for the largest share, owing to rise in cardiac ailments among geriatrics, and availability of low-cost alternatives

Oral segment accounted for the larger market share, owing to the advantages of oral based drug administration with minimal nursing experience, with high accept patient acceptability

Retail pharmacy is projected to experience larger revenue share, primarily due to increase in number of retail pharmacies in the developed markets

APAC is projected to register a higher growth rate in the study period, due to increase in preference of low-cost medicines

The global players include: Teva Pharmaceutical, Lupin, Sanofi, Sun Pharmaceutical Industries, Dr. Reddy's Laboratories, Endo International, GlaxoSmithKline, Pfizer, Apotex, and Viatris, Inc.

Polaris Market Research has segmented the branded generics market report based on drug class, application, route of administration, by distribution channel, and region:

Branded Generics, Drug Class Outlook (Revenue - USD Billion, 2019 - 2032)

Branded Generics, Application Outlook (Revenue - USD Billion, 2019 - 2032)

Branded Generics, Route of Administration Outlook (Revenue - USD Billion, 2019 - 2032)

Branded Generics, Distribution Channel Industry Outlook (Revenue - USD Billion, 2019 - 2032)

Branded Generics, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

Table of Contents

1. Introduction

2. Executive Summary

3. Research Methodology

4. Global Branded Generics Market Insights

5. Global Branded Generics Market, by Drug Class

6. Global Branded Generics Market, by Application

7. Global Branded Generics Market, by Distribution Channel

8. Global Branded Generics Market, by Geography

9. Competitive Landscape

10. Company Profiles

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â